Europe could beat U.S. in biopharma innovation
Europe could overthrow the U.S. as a leader in the biotech-drug industry if U.S. lawmakers decide to shorten intellectual property protection for brand-name biologics under proposed legislation, writes Benedetto Della Vedova, former member of the European Parliament. A proposal to provide five to seven years of protection -- shorter than Europe's 10 years -- would stifle innovation and diminish the chance of U.S. companies to be globally competitive, giving way for European firms to create the next generation of biotech treatments, Della Vedova writes.
Wall Street Journal, The
| 11/12
This story published in BIO SmartBrief on 11/13/2009
|
BIO SmartBrief
Designed specifically for biotechnology industry professionals like you, BIO SmartBrief is a FREE daily e-mail newsletter. It provides the latest news and information you need to stay informed about important biotech issues. Learn more |
|